David J. Mazzo, PhD
Chief Executive Officer and Director
Dr. Mazzo earned a BA in the Honors Program (interdisciplinary humanities) and a BS in chemistry from Villanova University. In addition, Dr. Mazzo received his MS in chemistry and his PhD degree in analytical chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.
Douglas W. Losordo, MD, FACC, FAHA
Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
Dr. Losordo has engaged in career-long efforts to develop novel therapeutics and as a scientist he obtained over $35 million in National Institutes of Health funding, for discovering and developing new therapeutic concepts in the laboratory, providing the basis for clinical studies. He has led first in human studies in multiple gene and adult stem cell therapies in patients with cardiovascular diseases, including therapies now in Phase 3 testing. He is a highly sought after speaker, having given over 200 international lectures. He has served as an associate editor of Circulation Research, the basic science journal of the American Heart Association and serves on the editorial boards of a number of scientific journals. Since 2012, he has served on the Scientific Advisory Board of The Stem For Life Foundation, a public charity devoted to accelerating development of cell therapies.
Senior Vice President, Business Development
Prior to Caladrius Biosciences, Raj Prabhakar served as Vice President and Head of Business Development for Celsion Corporation from 2004 to 2015, including the acquisition of EGEN, Inc. a gene therapy and delivery company. At Celsion-EGEN, he led partnerships for immune-oncology gene therapy, small molecules, new formulations, and oligonucleotide delivery for DNA, RNA and gene editing candidates. Raj has particular transaction experience in Asia-Pacific with leading pharmaceutical companies in Japan and China. Prior to Celsion Raj was employed at PATH Global Vaccine Development Group, Protiveris, Osiris Therapeutics, and Harvard Medical School-Brigham & Women’s Hospital in multiple corporate development, business development, commercialization and research roles. Raj holds an MBA from the Harvard Business School and dual Bachelors of Science Degrees in Biology and Mechanical Engineering from the Massachusetts Institute of Technology.
Senior Vice President and Chief Financial Officer
Prior to joining Caladrius, from 1996 to 2010, Mr. Talamo held various senior positions at OSI Pharmaceuticals, Inc. (“OSI”), a publicly-traded biopharmaceutical company focused on discovering, developing and commercializing products for the treatment of cancer, diabetes and obesity, and most recently served as its Vice President and Corporate Controller from 2006 to 2010 and its Corporate Controller from 2002 to 2006. While at OSI, Mr. Talamo helped build the accounting and finance infrastructure to support the clinical development and commercial launch of Tarceva®, OSI's targeted therapy approved for the treatment of patients with non-small cell lung cancer and pancreatic cancer. Prior to OSI, Mr. Talamo worked at Bristol-Myers Squibb from 1995 to 1996 in the Financial Reporting and Consolidations Group, and at KPMG from 1993 to 1995 in the Health Care and Life Sciences Audit Group. Mr. Talamo has served as Treasurer of the Stem For Life Foundation, a public charity dedicated to raising awareness about adult stem cells and their therapeutic promise, since 2012. Mr. Talamo also served as Treasurer of the OSI Pharmaceuticals Foundation from 2008 to 2010.
Mr. Talamo received a BBA in accounting from Hofstra University in 1991, and an MBA in finance from Hofstra University in 1999. Mr. Talamo is a certified public accountant in the State of New York.
Todd Girolamo, JD
General Counsel and Corporate Secretary
Mr. Girolamo began his legal career as an associate at Cahill Gordon & Reindel, and he concluded his tenure in private practice at Reid & Priest, where he gained expertise as a general commercial litigator practicing in the areas of intellectual property, securities law, employment law and bankruptcy. In addition to over a decade of experience as both corporate counsel and private practitioner, Mr. Girolamo spent 12 years on Wall Street where he specialized in therapeutic healthcare equity securities at Oppenheimer & Co., CIBC World Markets, Leerink Swann & Company and Summer Street Research Partners.
Mr. Girolamo received a Bachelor of Arts from Harvard College, Juris Doctor from the University of Pennsylvania Law School and Master of Business Administration from Columbia Business School.
Vice President, Human Resources
Mr. Schloss comes to Caladrius (formerly NeoStem) with a strong resume of experience in the pharmaceutical and biotechnology industries. Prior to joining Caladrius, he served as SVP, Human Resources with PLUS Diagnostics (acquired by Miraca Life Sciences). Prior to PLUS Diagnostics, Mr. Schloss led human resources for OraPharma from 2011- 2012, a private equity owned specialty pharmaceutical company focused on oral health care. Mr. Schloss helped grow the company and was instrumental in its acquisition and integration by Valeant Pharmaceuticals International. Prior to OraPharma, from 2009-2011, Mr. Schloss was Vice President, Human Resources for Eurand Pharmaceuticals, a publicly traded specialty pharmaceutical company based in Italy that develops, manufactures and commercializes pharmaceutical and biopharmaceutical products. While with Eurand, Mr. Schloss helped build the commercial organization that launched Zenpep® for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. Eurand was acquired by Aptalis in 2011.
From 2007-2009, Mr. Schloss led human resources for ImClone Systems, a fully integrated global biopharmaceutical company, engaged in the development and commercialization of a portfolio of targeted biological oncology treatments. He also led ImClone System’s human resources through its acquisition by Eli Lilly in 2008. Additionally, Mr. Schloss spent 17 years with GlaxoSmithKline in a number of senior level HR roles across the US and internationally.
Before beginning his career in human resources, Mr. Schloss was an attorney practicing in the representation of management in all phases of labor relations and employment law. He earned a BA from Clark University and a J.D. from the University of Miami School Of Law. He currently serves on the Pennsylvania Advisory Board of the Devereux Foundation, a leading nonprofit behavioral health organization that provides support and services to children and adults with intellectual, emotional, developmental, and behavioral challenges.
Vice President, Information Technology
Greg Berkin joined Caladrius in January 2015. Since that time, Greg has been responsible for transforming external IT support into an internal team working as a highly efficient operating unit across all five Caladrius and PCT sites. He also manages all groups within IT: Networking, PC, Applications, Business Solutions, and Telecom.
Before joining Caladrius, Greg held director and management roles in IT at companies including Regado Biosciences, Aeterna Zentaris, and Chugai Pharma USA.
Greg has more than 20 years in the technical profession with 15 years of unparalleled managerial experience, specializing in production systems, network engineering, facility operations, project management, hybrid cloud-computing, and cybersecurity.